{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:15:11Z","timestamp":1779290111447,"version":"3.51.4"},"reference-count":1,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2000]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Between May 1995 and April 1996, 20 patients with Beh\u00e7et\u2019s disease were successfully treated with interferon \u03b1&lt;sub&gt;2a&lt;\/sub&gt; (IFN-\u03b1&lt;sub&gt;2a&lt;\/sub&gt;) 9 million IU\/day three times a week and 16 patients with colchicine 1.5 mg\/day orally for 3 months. &lt;i&gt;Objective:&lt;\/i&gt; To study the long-term effects of IFN treatment in Beh\u00e7et\u2019s disease. &lt;i&gt;Methods:&lt;\/i&gt; Between the years of 1996 and 1999, the patients were followed up every 3 months or whenever indicated. Retrospective evaluation was performed. &lt;i&gt;Results:&lt;\/i&gt; In 56% of the patients with complete remission or partial remission at the end of IFN-\u03b1&lt;sub&gt;2a&lt;\/sub&gt; treatment, long-term remissions ranging from 36 to 48 months were observed. &lt;i&gt;Conclusion:&lt;\/i&gt; IFN-\u03b1&lt;sub&gt;2a&lt;\/sub&gt; treatment is an effective treatment modality in Beh\u00e7et\u2019s disease with the advantage of inducing prolonged remissions.<\/jats:p>","DOI":"10.1159\/000018427","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T17:25:18Z","timestamp":1050427518000},"page":"40-43","source":"Crossref","is-referenced-by-count":22,"title":["Long-Term Effects of Interferon Alpha 2A Treatment in Beh\u00e7et\u2019s Disease"],"prefix":"10.1159","volume":"201","author":[{"given":"A.","family":"Boyvat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"\u015ei\u015fman-Solak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"G\u00fcrler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2000,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.8.1010"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/18427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/18427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:59:33Z","timestamp":1745470773000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000018427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2000,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000018427","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000]]}}}